Некоторое содержание этого приложения в настоящий момент недоступно.
Если эта ситуация сохраняется, свяжитесь с нами по адресуОтзывы и контакты
1. (WO2015188866) NOVEL COMPOUNDS
Примечание: Текст, основанный на автоматизированных процессах оптического распознавания знаков. Для юридических целей просьба использовать вариант в формате PDF

CLAIMS

1. A compound selected from the group consisting of

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3a]pyrimidin-5-yl]-phenyl}-ethyl)-4-methoxy-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-3-hydroxy-pyridinium bromide;

1 -(2- {5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2-methyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-4-hydroxymethyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-4-isopropyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-5-hydroxy-2-methyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2,4-dimethyl-pyridinium bromide;

1 -(2- {5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-3,5-dimethyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-

phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2-ethyl-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluorornethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-2-(2-hydroxy-ethyl)-pyridinium bromide;

l-(2-{5-Cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[l,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-ethyl)-4-ethyl-pyridinium bromide;

and the pharmaceutically acceptable salts thereof.

2. A compound of formula (I)" or a pharmaceutically acceptable salt thereof


CO"

wherein the group R is selected in the group consisting of

- 4-methoxy-pyridinyl;

- 3-hydroxy-pyridinyl;

- 2-methyl-pyridinyl;

- 4-hydroxymethyl-pyridinyl;

- 4-isopropyl-pyridinyl;

- 5-hydroxy-2-methyl-pyridinyl;

- 2,4-dimethyl-pyridinyl;

- 3,5-dimethyl-pyridinyl;

- 2-ethyl-pyridinyl;

- 2-(2-hydroxy-ethyl)-pyridinyl; and

- 4-ethyl-pyridinyl.

3. A pharmaceutical composition comprising a compound as claimed in claims 1 or 2 and a pharmaceutically acceptable carrier or excipient.

4. A pharmaceutical composition as claimed in claims 1 or 2 which is adapted for oral administration or administration by the pulmonary route.

5. A compound as claimed in claims 1 or 2 for the treatment of, or for use in the manufacture of a medicament for use in the treatment of, a disease or condition in which HNE is implicated.

6. A method of treatment of a disease or condition in which HNE is implicated, comprising administering to a subject suffering such disease an effective amount of a compound as claimed in claims 1 or 2.

7. A compound for use according to claims 1 or 2, or a method of treatment according to claim 5, wherein the disease or condition is chronic obstructive pulmonary disease (COPD), bronchiectasis, chronic bronchitis, lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, smoking-induced emphysema or cystic fibrosis.

8. A compound for use according to claims 1 or 2 or a method of treatment according to claim 6, wherein the disease or condition is asthma, rhinitis, psoriasis, atopic dermatitis, non-atopic dermatitis, Crohn's disease, ulcerative colitis, or irritable bowel disease.